ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0986

The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis

Session Information

  • Peritoneal Dialysis
    November 04, 2021 | Location: On-Demand, Virtual Only
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Lin, Chih-Ching, Taipei Veterans General Hospital, Taipei, Taiwan
  • Niu, Chih-Yuan, Taipei Veterans General Hospital, Taipei, Taiwan

Peritoneal dialysis (PD) is a treatment modality for end-stage renal disease (ESRD) patients. Dextrose is a common osmotic agent used in PD solutions and its absorption may exacerbate diabetes mellitus. PD solutions also contain glucose degradation products (GDPs) that may lead to encapsulating peritoneal sclerosis (EPS). A previous study showed that far-infrared (FIR) therapy improved a patient's gastrointestinal symptoms due to EPS. Due to limited literature, this study aims to investigate dialysate GDPs and peritoneal function in diabetic patients on PD.


A prospective analysis conducted in a single center. The participants were recruited from the peritoneal dialysis outpatient department from November 25, 2016 to September 5, 2018. We included the patients who met the following criteria: (1) ESRD patients aged 20–90 years without receiving FIR therapy within 12 months; (2) receiving continuous ambulatory peritoneal dialysis or automated peritoneal dialysis; (3) no history of peritonitis, cerebrovascular accident, myocardial infarction, or receiving any cardiovascular intervention in the past 3 months. Patients were allocated to two groups based on their underlying DM history. Both groups of PD patients received FIR therapy for 6 months. We collected the last daily bag of peritoneal dialysate and compared the dialysate concentration of GDPs and clinical data in PD patients pre- and post-FIR therapy.


Thirty-one PD patients were enrolled and underwent 40 min of FIR therapy twice daily for six months. We demonstrated the effect of FIR therapy on the following: (1) decrease of methylglyoxal (p = 0.02), furfural (p = 0.005), and 5-hydroxymethylfurfural (p = 0.03), (2) increase of D/D0 glucose ratio (p = 0.03), and (3) decrease of potassium levels (p = 0.008) in both DM and non-DM patients, as well as (4) maintenance and increase of peritoneal Kt/V in DM and non-DM patients, respectively (p = 0.03). FIR therapy is a non-invasive intervention that can decrease dialysate GDPs in PD patients by improving peritoneal transport rate and solute removal clearance, while also maintaining dialysis adequacy.


In conclusion, our study demonstrated that FIR therapy can decrease PD patients’dialysate GDPs by improving peritoneal transport rate and solute removal clearance, while also maintaining dialysis adequacy.